Specific medication-related counseling:

Question 1

Fingolimod (Gilenya) 0.5 mg once daily counselling:

Answer 1

It is a sphingosine-1-phosphate (S1P) receptor, blocks lymphocytes’ ability to emerge from lymph nodes, reducing the number of lymphocytes available to the CNS

Doses in Children ≥10 years and Adolescents:

≤40 kg: Oral: 0.25 mg once daily

> 40 kg: Oral: 0.5 mg once daily

• First-dose, 6-hour monitoring is recommended for all patients.
• Interrupt therapy if: ALT >3 times ULN & total bilirubin >2 times ULN
• Hazardous agent (NIOSH 2016 [group 2]). wear single gloves.
• Avoid live-attenuated vaccines in patients who currently receive or have recently discontinued fingolimod
• Avoid pregnancy during therapy and for 2 months after discontinuing treatment
• CI: HF, baseline QTc interval ≥500 msec; concurrent use of a class Ia or III antiarrhythmic, pregnancy and women in childbearing years not using effective contraception.